Dr. Clara Hwang
Claim this profileHenry Ford Hospital
Studies Prostate Cancer
Studies Transitional Cell Carcinoma
8 reported clinical trials
15 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
2Transitional Cell Carcinoma
HER2 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Clara Hwang is currently running
Disitamab Vedotin + Pembrolizumab
for Bladder Cancer
This trial is testing a new drug called disitamab vedotin, alone or with pembrolizumab, for patients with advanced or metastatic HER2 expressing bladder cancer. Disitamab vedotin is designed to target HER2 and has been approved for other types of cancer. The study aims to see if these drugs can effectively treat the cancer and what side effects they might cause.
Recruiting1 award Phase 24 criteria
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of bladder cancer patients who have undergone surgical removal of their bladder.
Recruiting1 award Phase 2 & 310 criteria
More about Clara Hwang
Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Clara Hwang has experience with
- Pembrolizumab
- Abiraterone Acetate
- Fuzuloparib
- Prednisone
- Fuzuloparib Placebo
- Futibatinib
Breakdown of trials Clara Hwang has run
Prostate Cancer
Transitional Cell Carcinoma
Bladder Cancer
Skin Cancer
Uterine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Clara Hwang specialize in?
Clara Hwang focuses on Prostate Cancer and Transitional Cell Carcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Clara Hwang currently recruiting for clinical trials?
Yes, Clara Hwang is currently recruiting for 3 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Clara Hwang has studied deeply?
Yes, Clara Hwang has studied treatments such as Pembrolizumab, Abiraterone acetate, Fuzuloparib.
What is the best way to schedule an appointment with Clara Hwang?
Apply for one of the trials that Clara Hwang is conducting.
What is the office address of Clara Hwang?
The office of Clara Hwang is located at: Henry Ford Hospital, Detroit, Michigan 48202 United States. This is the address for their practice at the Henry Ford Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.